



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 411/04, C07F 5/04 A61K 31/505		A1	(11) International Publication Number: WO 92/14729 (43) International Publication Date: 3 September 1992 (03.09.92)
(21) International Application Number: PCT/US92/01393 (22) International Filing Date: 21 February 1992 (21.02.92) (30) Priority data: 659,760 22 February 1991 (22.02.91) US 736,089 26 July 1991 (26.07.91) US 803,028 6 December 1991 (06.12.91) US (60) Parent Applications or Grants (63) Related by Continuation US 659,760 (CIP) Filed on 22 February 1991 (22.02.91) US 736,089 (CIP) Filed on 26 July 1991 (26.07.91) US 803,028 (CIP) Filed on 6 December 1991 (06.12.91) (71) Applicant (for all designated States except US): EMORY UNIVERSITY (US/US); 1380 South Oxford Road, Atlanta, GA 30322 (US).		(72) Inventors; and (73) Inventors/Applicants (for US only): LIOTTA, Dennis, C. [US/US]; 793 Post Road Way, Stone Mountain, GA 30088 (US). SCHINAZI, Raymond, F. [US/US]; 1524 Regency Walk Drive, Decatur, GA 30033 (US). (74) Agents: ZALESKY, Cheryl, K. et al.; Kilpatrick & Cody, 100 Peachtree Street, Suite 3100, Atlanta, GA 30303 (US). (81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), MC (European patent), NL (European patent), SE (European patent), US. Published With international search report. Before the expiration of the time limit for amending the claims and in the event of the receipt of amendments.	
(54) Title: ANTIVIRAL 1,3-DIOXOLANE NUCLEOSIDES AND SYNTHESIS THEREOF			
(57) Abstract A synthesis of 1,3-dioxolane nucleosides that includes condensing a 2-O-protected-5-O-acylated-1,3-dioxolane with a purine or pyrimidine base in the presence of a titanium containing Lewis acid to provide predominately the desired β -isomer in the C1'-position of a 1,3-dioxolane nucleoside. A process for the resolution of a racemic mixture of 1,3-dioxolane nucleoside enantiomers is also disclosed that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. This invention includes: the compounds (\pm)-2'-deoxy-5-fluoro-3'-oxacytidine, (-)-2'-deoxy-5-fluoro-3'-oxacytidine, and (+)-2'-deoxy-5-fluoro-3'-oxacytidine; (\pm)- β -D,L-2'-deoxy-5-fluoro-3'-oxacytidine, its (-) and (+) enantiomers, and pharmaceutically acceptable derivatives and salts thereof for use in medical therapy, for example for the treatment or prophylaxis of an HIV infection; and use of (\pm)- β -D,L-(\pm)- β -D,L-2'-deoxy-5-fluoro-3'-oxacytidine, its (-) and (+) enantiomers, and pharmaceutically acceptable derivatives and salts thereof in the manufacture of a medicament for treatment of an HIV infection.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	MI	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				
ES	Spain				

ANTIVIRAL 1, 3 -DIOXOLANE NUCLEOSIDES AND SYNTHESIS THEREOF

The U.S. Government has rights in this invention arising out of National Institutes of Health Grant No. AI-28731 and No. AI-26055.

Background of the Invention

The invention described herein includes a stereoselective synthesis of 1,3-dioxolane nucleosides, and antivirally active 1,3-dioxolane nucleosides.

In 1981, acquired immune deficiency syndrome (AIDS) was identified as a disease that severely compromises the human immune system, and that almost without exception leads to death. In 1983, the etiological cause of AIDS was determined to be the human immunodeficiency virus (HIV). In December, 1990, the World Health Organization estimated that between 8 and 10 million people worldwide were infected with HIV, and of that number, between 1,000,000 and 1,400,000 were in the United States.

In 1985, it was reported that the synthetic nucleoside 3'-azido-3'-deoxythymidine (AZT) inhibits the replication of human immunodeficiency virus type 1. Since then, a number of other synthetic nucleosides, including 2',3'-dideoxyinosine (DDI), 2',3'-dideoxycytidine (DDC), 3'-fluoro-3'-deoxythymidine (FLT), 2',3'-dideoxy,2',3'-didehydrothymidine (D4T), and 3'-azido-2',3'-dideoxyuridine (AZDU), have been proven to be effective against HIV. A number of other 2',3'-dideoxynucleosides have been demonstrated to inhibit the growth of a variety of other viruses *in vitro*. It appears that, after cellular phosphorylation to the 5'-triphosphate by cellular kinases, these synthetic nucleosides are incorporated into a growing strand of viral DNA, causing chain termination due to the absence of the 3'-hydroxyl group.

Both DDC and D4T are potent inhibitors of HIV replication with activities comparable (D4T) or superior (DDC) to AZT. However, both DDC and D4T are not efficiently converted to the corresponding 5'-triphosphates *in vivo* and are resistant to deaminases and phosphorylases. Both compounds are also toxic.

The success of various 2',3'-dideoxynucleosides in inhibiting the replication of HIV *in vivo* or *in vitro* has led a number of researchers to design and test nucleosides that substitute a heteroatom for the carbon atom at the 3'-position of the nucleoside. Norbeck, et al., disclose that (\pm)-1-[(2B,4B)-2-(hydroxymethyl)-4-dioxolanyl]thymine (referred to below as (\pm)-dioxolane-T or DOT, see Figure 2), a 1,3 dioxolane nucleoside, exhibits a modest activity against HIV (EC_{50} of 20 μ m in ATH8 cells), and is not toxic to uninfected control cells at a concentration of 200 μ m. Tetrahedron Letters 30 (46), 6246, (1989). In light of the fact that this compound exhibits efficacy against HIV and has very low toxicity, it is desirable to develop suitable synthetic protocols for preparing a wide variety of analogs and isomers of this compound.

To market a nucleoside for pharmaceutical purposes, it must not only be efficacious with low toxicity, it must also be cost effective to manufacture. An extensive amount of research and development has been directed toward new, low cost processes for large scale nucleoside production.

2',3'-Dideoxynucleosides are currently prepared by either of two routes; derivatization of an intact nucleoside or condensation of a derivatized sugar moiety with a heterocyclic base. Although there are numerous disadvantages associated with obtaining new nucleoside analogues by modifying intact nucleosides, a major advantage of this approach is that the appropriate absolute stereochemistry has already been set by nature. Obviously, this approach cannot be used in the production

of nucleosides that contain either nonnaturally occurring bases or nonnaturally occurring carbohydrate moieties (and which therefore are not prepared from intact nucleosides), such as 1,3-dioxolane nucleosides.

When condensing a carbohydrate-like moiety such as a 1,3-dioxolane with a heterocyclic base to form a synthetic nucleoside, a nucleoside is produced that has two chiral centers (at the C1' and C4' positions, see Figure 1), and thus exists as a diastereomeric pair. Each diastereomer exists as a set of enantiomers. Therefore, the product is a mixture of four enantiomers. It is often found that nucleosides with nonnaturally-occurring stereochemistry in either the C1' or the C4' positions are less active than the same nucleoside with the stereochemistry as set by nature.

It is well known in the art that the stereoselective introduction of bases to the anomeric centers of carbohydrates can be controlled by capitalizing on the neighboring group participation of a 2-substituent on the carbohydrate ring [Chem. Ber. 114:1234 (1981)]. However, dioxolanes do not possess an exocyclic 2-substituent and, therefore, cannot utilize this procedure unless additional steps to introduce a functional group that is both directing and disposable are incorporated into the synthesis. These added steps would lower the overall efficiency of the synthesis.

It is also well known in the art that "considerable amounts of the undesired α -nucleosides are always formed during the synthesis of 2'-deoxyribosides" [Chem. Ber. 114:1234, 1244 (1981)]. Furthermore, this reference teaches that the use of simple Friedel-Crafts catalysts like SnCl₄ in nucleoside syntheses produces undesirable emulsions upon the workup of the reaction mixture, generates complex mixtures of the α and β -isomers, and leads to stable δ -complexes between the SnCl₄ and the more basic silylated heterocycles such as silylated cytosine. These complexes

lead to longer reaction times, lower yields, and production of the undesired unnatural N-3-nucleosides.

Therefore, it is an object of the present invention to provide a method for the synthesis of a variety of 1,3-dioxolane nucleosides that includes condensing a 1,3-dioxolane moiety with a purine or pyrimidine base through a process that provides high β -stereoselectivity at the C1' position.

It is another object of the present invention to provide a method for the resolution of racemic mixtures of 1,3-dioxolane nucleosides at the C4'-position.

It is another object of the present invention to provide new antiviral agents, pharmaceutical compositions, and methods of treatment.

Summary of the Invention

The invention as disclosed includes a method for the synthesis of 1,3-dioxolane nucleosides that includes condensing a suitably protected 1,3-dioxolane moiety with a heterocyclic base, typically a purine or pyrimidine base, to provide a 1,3-dioxolane nucleoside with high β -stereoselectivity in the C1'-position. The method can be used to prepare the C₁- β anomer of biologically active 1,3-dioxolane nucleosides such as 2'-deoxy-5-fluoro-3'-oxacytidine (FDOC), 2'-deoxy-3'-oxacytidine (DOC), and 2'-deoxy-3'-oxathymidine (DOT). The method includes condensing a protected 1,3-dioxolane with a suitably protected purine or pyrimidine base in the presence of a titanium-based Lewis acid of the structure:



wherein $m = 4$; $n = 2, 3$, or 4 ; Ti = titanium; $X = \text{Cl, Br, or I}$; and Y is alkoxy, aryloxy, amino, alkylamino, dialkylamino, mixtures thereof, or a bifunctional molecule that contains both an alkoxy and an amino

functional group and that is bound to the titanium molecule by both the alkoxy and amino moieties.

A process for the resolution of a racemic mixture of 1,3-dioxolane nucleoside enantiomers is also disclosed that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The process can be used to resolve a wide variety of 1,3-dioxolane nucleosides, including pyrimidine and purine nucleosides that are optionally substituted in the carbohydrate moiety or base moiety. The resolution of 1,3-dioxolane nucleosides can be performed on large scale at moderate cost.

A number of 1,3-dioxolane nucleosides described herein have antiviral activity, including anti-HIV activity. The anti-viral activity of the described nucleosides can be evaluated by the method described herein, or as otherwise known to those skilled in the art.

This invention includes:

the compounds (\pm) -2'-deoxy-5-fluoro-3'-oxacytidine, $(-)$ -2'-deoxy-5-fluoro-3'-oxacytidine, and $(+)$ -2'-deoxy-5-fluoro-3'-oxacytidine;

(\pm) -B-D,L-2'-deoxy-5-fluoro-3'-oxacytidine, its $(-)$ and $(+)$ enantiomers, and pharmaceutically acceptable derivatives and salts thereof for use in medical therapy, for example for the treatment or prophylaxis of an HIV infection;

and use of (\pm) -B-D,L-(\pm)-B-D,L-2'-deoxy-5-fluoro-3'-oxacytidine, its $(-)$ and $(+)$ enantiomers, and pharmaceutically acceptable derivatives and salts thereof in the manufacture of a medicament for treatment of a HIV infection.

Brief Description of the Figures

Figure 1 is an illustration of the chemical structure of a 1,3-dioxolane nucleoside that indicates the position of the two chiral carbon atoms (C1' and C4') in the molecule.

Figure 2 is an illustration of chemical structures of intermediates used in the reaction scheme for the preparation of 2'-deoxy-3'-oxa-cytidine (DOC, compound 10), 3'-deoxy-3'-oxa-thymidine (DOT, compound 11), and 2'-deoxy-5-fluoro-3'-oxa-cytidine (FDOC, compound 13).

Detailed Description of the Invention

As used herein, the term "enantiomerically enriched nucleoside" refers to a nucleoside composition that includes at least 95% of a single enantiomer of that nucleoside.

As used herein, the term FDOC refers to 2'-deoxy-5-fluoro-3'-oxacytidine, also known as 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-dioxolane.

As used herein, the term DOC refers to 2'-deoxy-3'-oxacytidine, also known as 2-hydroxymethyl-5-(cytosin-1-yl)-1,3-dioxolane.

As used herein, the term DOT or dioxolane-T refers to 2'-deoxy-3'-oxathymidine, also known as 2-hydroxymethyl-5-(thymidin-1-yl)-1,3-dioxolane.

As used herein, the term "preferential enzyme catalysis" refers to catalysis by an enzyme that favors one substrate over another.

As used herein, the term "1,3-dioxolane nucleoside" refers to a nucleoside in which a purine or pyrimidine base is attached to a 1,3-dioxolane ring through the C5 carbon of the dioxolane (which becomes the C1'-carbon of the nucleoside), as shown in Figure 1.

As used in this application, the term "predominately" means greater than 80%.

As used herein, the term "protected" means that the functional group, typically an oxygen or nitrogen atom, has been protected by any method known to those skilled in the art for the protection of that group.

As used herein, the term "acylation" means replacement of an H

in a functional group of interest with XC(O) , wherein X is an alkyl or aromatic group, typically a lower alkyl (C5 or less).

As used herein, the term "alkoxy" refers to an alkyl-O-moiety, wherein the alkyl group can be straight chain, branched, or cyclic.

As used herein, the term "aryloxy" refers to $\text{C}_6\text{H}_5\text{-O-}$, or a derivative thereof in which there is one or more hydrocarbon, halo, or other substituents on the aromatic ring.

As used herein, the term "alkylamino" refers to alkyl-NH-, wherein the alkyl group is straight chain, branched, or cyclic.

As used herein, the term "dialkylamino" refers to $(\text{alkyl})_2\text{N-}$, wherein the alkyl group is straight chain, branched, or cyclic.

As used herein, the term "arylamino" refers to $\text{C}_6\text{H}_5\text{-NH-}$, or a derivative thereof in which there is one or more hydrocarbon, halo, or other substituents on the aromatic ring.

As used herein, the term "diarylamino" refers to $(\text{C}_6\text{H}_5)_2\text{-N-}$, or a derivative thereof in which there is one or more hydrocarbon, halo, or other substituents on the aromatic rings.

As used herein the term "alkylarylamino" refers to $(\text{C}_6\text{H}_5)(\text{alkyl})\text{N-}$, or a derivative thereof in which there is one or more hydrocarbon, halo, or other substituents on the aromatic ring, and wherein the alkyl group is straight chain, branched, or cyclic.

I. Preparation of Predominately the β -Anomer of 1,3-Dioxolane Nucleosides

A synthesis of 1,3-dioxolane nucleosides is disclosed that includes condensing a 2-O-protected-5-O-acylated-1,3-dioxolane with a purine or pyrimidine base in the presence of a titanium containing Lewis acid of the structure:



wherein $m = 4$; $n = 2, 3$, or 4 ; Ti = titanium; $X = \text{Cl, Br, or I}$; and Y is alkoxy, aryloxy, amino, alkylamino, dialkylamino, arylamino,

diarylamino, alkylarylamino, and mixtures thereof, or a bifunctional molecule that contains both an alkoxy and an amino functional group and that is bound to the titanium molecule by both the alkoxy and amino moieties, to provide predominately the desired β -isomer in the C1'-position of a 1,3-dioxolane nucleoside.

The process can be used to prepare a wide variety of 1,3-dioxolane nucleosides, including those with a cytosine, thymine, uracil, adenine, or guanine base, and alkylated, halogenated, sulfenylated, and alkoxylated derivatives thereof.


Nonlimiting examples of suitable alkoxy groups that can be present in the titanium catalyst include isopropoxide (Oipr), and other lower alkoxy groups (C₃ or less). A nonlimiting example of suitable aryloxy groups include phenoxy. Nonlimiting examples of suitable alkylamine and dialkylamine groups that can be present in the titanium catalyst include those with lower alkyl groups (C₃ or less). Examples of suitable arylamino groups that can be present in the titanium catalyst include those with phenyl groups. Examples of bifunctional molecules that contain both an alkoxy and an amino functional group and that can be bound to the titanium molecule by both the alkoxy and amino moieties include 2-aminoethanol, 3-aminopropanol, and 1-substituted and 2-substituted derivatives thereof in which the substituents are lower alkyl (C₃ or less) or aryl groups.

The condensation reaction can be carried out under any conditions that provide predominately the β -isomer of the 1,3-dioxolane nucleoside. The reaction is typically carried out in a nonprotic, noncoordinating solvent such as toluene, chloroform, dichloromethane, or carbon tetrachloride, at a temperature typically ranging from -80°C to room temperature (with elevated temperature used if needed to force the reaction). The reaction is monitored by thin layer chromatography until

complete. In certain situations, if the product is allowed to remain in the presence of the Lewis acid for too long, epimerization may occur. The product is purified by conventional methods known to those skilled in the art, including chromatography and recrystallization.

The stereoselectivity of these N-glycosylation reactions can be rationalized on the basis of a preferential heteroatom Lewis acid interaction (Scheme 1, below). Use of Lewis acids (e.g., trimethylsilyl trifluoromethanesulfonate) whose role is solely to generate an oxonium ion, should follow Pathway A and result in no stereocontrol. However, in cases where the Lewis acid can pre-complex to a ring heteroatom (i.e., Pathway B), diastereofacial selectivity can be achieved through the minimization of destabilizing 1,2-steric interactions by complexing *anti* to the protected hydroxymethyl substituent. At the very least, this complexation should dramatically hinder the approach of the silylated base to the α -face. In addition, an intermediate can be formed wherein the associated metal delivers one of its ligands (presumably chloride) to the α -face of the proximal incipient carbonium ion. The resulting α -chloro derivative can then undergo S_N2 attack to form the B-N-glycoside.

-10-



Scheme 1

As examples, β -FDOC, β -DOC and β -DOT can be prepared by coupling a 2-protected hydroxymethyl-4-carboxy-1,3-dioxolane with the appropriate silylated pyrimidine base at ambient temperature using the Lewis acid, TiCl_4 . Removal of the protecting groups give the free nucleosides β -FDOC, β -DOC, β -DOT or analogues thereof. NMR stereochemical assignments and X-ray structures confirm the β selectivity.

Figure 2 is an illustration of chemical structures of intermediates used in the reaction scheme set out in detail below for the preparation of 2'-deoxy-3'-oxa-cytidine (DOC, compound 10), 3'-deoxy-3'-oxa-thymidine (DOT, compound 11), and 2'-deoxy-5-fluoro-3'-oxa-cytidine (FDOC, compound 13).

The 1,3-dioxolane ring can be prepared by known methods. In one method, an allyl ether or ester 1 is ozonized (see Figure 2) to give an aldehyde 3, which reacts with glycolic acid to give a lactone 4. The lactone 4 is treated with a reducing agent such as DIBAL (diisobutylaluminum chloride), Red Al (bis(2-methoxyethoxy)aluminum hydride), and $\text{LiAl}(\text{O}-t\text{-butyl})_2\text{H}$, followed by a carboxylic anhydride, to produce the carboxylate 5. This carboxylate is coupled with a silylated pyrimidine base 8 or a silylated 5-fluoro substituted pyrimidine base 7 in the presence of a titanium containing Lewis acid that can catalyze stereoselective coupling, including TiCl_4 , $\text{TiCl}_4(\text{OiPr})$ or $\text{TiCl}_4(\text{OiPr})_2$, wherein OiPr refers to isopropoxide, to yield the β -isomer of the nucleoside 9 or substituted nucleoside 12 in a high ratio of β : α isomers. The nucleoside 9 or substituted nucleoside 12 is deprotected to produce 10 or 13 or modified at the 5'-position to form a 1,3-dioxolane prodrug analogue.

The term "silylated pyrimidine or purine base", as used herein, refers to a pyrimidine or purine wherein the functional oxygen and nitrogen groups have been protected with suitable silyl moieties. Silyl

protecting groups are known to those skilled in the art, and include trialkylsilyl groups of the formula $-\text{Si}(\text{R}_1)(\text{R}_2)(\text{R}_3)$ wherein R_1 , R_2 , and R_3 are lower-alkyl, e.g., methyl, ethyl, butyl, and alkyl possessing 5 carbon atoms or less, or phenyl. Furthermore, R_1 can be identical to R_2 , and R_1 , R_2 , and R_3 can all be identical. Examples of trialkylsilyl groups include, but are not limited to, trimethylsilyl and t-butyldiphenylsilyl.

As used herein, a leaving group means a functional group that forms an incipient carbocation when it leaves.

Illustrative examples of the synthesis of dioxolane nucleosides according to the present invention are given in Example 1 below.

Example 1 - Synthesis of Dioxolane Nucleosides

Figure 2 illustrates the synthesis of 2'-deoxy-3'-oxacytidine (DOC), 2'-deoxy-3'-oxathymidine (DOT), and 2'-deoxy-5-fluoro-3'-oxacytidine (FDOC).

The synthesis of the 1,3-dioxolane moiety begins with allyl alcohol 1. A NaH oil suspension (4.5 g, 60%, 110 mmol) was washed with THF twice (100 ml x 2) and the resulting solid suspended in the THF (300 ml). The suspension was cooled to 0°C, allyl alcohol 1 (6.8 ml, 100 mmol) was added dropwise, and the mixture was stirred for 30 minutes at 0°C. t-Butyl-diphenylsilyl chloride (25.8 ml, 100.8 mmol) was added dropwise at 0°C and the reaction mixture was stirred for 1 hour at 0°C. The solution was quenched with water (100 ml), and extracted with diethyl ether (200 ml x 2). The combined extracts were washed with water, dried over MgSO_4 , filtered, concentrated, and the residue distilled under vacuum (90-100°C at 0.5-0.6 mm Hg) to give a colorless liquid 2 (28 g., 94 mmol, 94%). (^1H NMR: (CDCl_3 , 300 MHz) 7.70-7.35 (10H, m, aromatic-H); 5.93 (1H, m, H_2); 5.37 (1H, dt, H_1) $J=1.4$ and 14.4 Hz; 5.07 (1H, dt, H_1) $J=1.4$ and 8.7 Hz; 4.21 (2H, m, H_3); 1.07 (9H, s, t-Bu)).

The silyl allyl ether **2** (15.5 g, 52.3 mmol) was dissolved in CH_2Cl_2 (400 ml), and ozonized at -78°C . Upon completion of ozonolysis, DMS (15 ml, 204 mmol, 3.9 eq) was added at -78°C and the mixture was warmed to room temperature and stirred overnight. The solution was washed with water (100 ml x 2), dried over MgSO_4 , filtered, concentrated, and distilled under vacuum ($100-110^\circ\text{C}$ at 0.5-0.6 mm Hg) to give a colorless liquid, a silylated glycoaldehyde **3** ((15.0 g, 50.3 mmol, 96%). (^1H NMR: (CDCl_3 , 300 MHz) 9.74 (1H, s, H-CO); 7.70-7.35 (10H, m, aromatic-H); 4.21 (2H, s, $-\text{CH}_2$); 1.22 (9H, s, t-Bu)).

Alternative route to Compound 3

bis-t-Butyldiphenylsilyl ether of cis-2-butene-1,3-diol

NaH oil suspension (4.5 g, 60%, 110 mmol) was washed with THF twice (100 ml x 2) and the resulting solid suspended in THF (300 ml). The suspension was cooled to 0°C , and to it was added allyl alcohol (6.8 ml, 100 mmol) dropwise, and the mixture was stirred for 0.5 h at 0°C . t-Butyldiphenylsilyl chloride (25.8 ml, 100.8 mmol) was added dropwise at 0°C , and the reaction mixture stirred for 1 h at 0°C . The solution was quenched with water (100 ml), and extracted with Et_2O (200 ml x 2). The combined extracts were washed with water, dried over MgSO_4 , filtered, concentrated, and the residue was distilled under vacuum ($90-100^\circ\text{C}$ at 0.5-0.6 mm Hg) to give a colorless liquid bis-t-butyldiphenylsilyl ether of cis-2-butene-1,3-diol (28 g, 94 mmol, 94%). (^1H NMR: (CDCl_3 , 300 MHz) 7.70-7.35 (10H, m, aromatic H), 5.93 (1H, m, H_2), 5.37 (1H, dt, H_1 , $J=14.4$ Hz), 5.07 (1H, dt, H_1 , $J=1.4$ and 8.7 Hz), 4.21 (2 H, m, H_2), 1.07 (9H, s, t-Bu).

Ozonolysis of bis-t-Butyldiphenylsilyl ether of cis-2-butene-1,3-diol. bis-t-Butyldiphenylsilyl ether of cis-2-butene-1,3-diol (15.5 g, 52.3 mmol) was dissolved in CH_2Cl_2 (400 ml), and ozonized at -78°C . Upon completion of ozonolysis, dimethyl sulfide (15 ml, 204 mmol, 3.9 eq) was

added at -78°C , and the mixture was warmed to room temperature and stirred overnight. The solution was washed with water (100 ml x 2), dried over MgSO_4 , filtered, concentrated, and distilled under vacuum ($100-110^{\circ}\text{C}$ at 0.5-0.6 mm Hg) to give a colorless liquid aldehyde (15.0 g, 50.3 mmol, 96%).

$^1\text{H NMR}$: (CDCl_3 , 300 MHz) 9.74 (1H, s, H-CO), 7.70-7.35 (10H, m, aromatic H), 4.21 (2H, s, $-\text{CH}_2-$), 1.22 (9H, s, t-Bu); IR (Neat) 3080, 3060, 2970, 2940, 2900, 2870, 1730, 1470, 1460, 1430, 1390, 1360, 1310, 1200, 1110, 1030, 960, 880, 830, 745, 710.

A portion of the silylated glycoaldehyde **3** (4.0 g, 13.40 mmol) was dissolved in 1,2-dichloroethane (50 ml) and to it was added glycolic acid (1.10 g, 14.46 mmol) in one portion and p-toluenesulfonic acid (0.1 g). The mixture was refluxed for 1 hour. The volume of the solution was then reduced to about half by distilling off the solvent with a Dean-Stark trap. Another 50 ml of dichloroethane was added and the solution refluxed for 30 minutes again. The solution was cooled to room temperature and concentrated under vacuum. The residue was dissolved in ether (200 ml) and the solution washed with NaHCO_3 solution (50 ml) and water (50 ml). The combined extracts were dried over MgSO_4 , filtered, and concentrated to give a colorless oil which gradually solidified under vacuum. Recrystallization from hexane afforded a waxy white solid **4** (2-(t-Butyl-diphenylsilyloxy)-methyl-4-oxo-1,3-dioxolane) (4.2 g, 11.78 mmol, 88%). ($^1\text{H NMR}$: (CDCl_3 , 300 MHz) 7.66 & 7.42 (10H, m, aromatic-H), 5.72 (1H, broad, H₂), 4.46 (1H, d, 1H₂, $J=14.4$ Hz), 4.28 (1H, d, 1H₂, $J=14.4$ Hz), 3.81 (2H, d, 2CH₂O, $J=1.8$ Hz), 1.04 (9H, s, t-Bu); mp $94-95^{\circ}\text{C}$; MS (FAB) 357 (M+H), 299, 241, 197, 163, 135, 91; Anal. Calc'd for $\text{C}_{20}\text{H}_{24}\text{O}_4\text{Si}$: C, 67.38; H, 6.79; Found: C, 67.32; H, 6.77).

4-Acetoxy-2-(t-Butyldiphenylsilyloxymethyl)-1,3-dioxolane **29** was prepared using either of the following procedures A or B.

-15-

Procedure A: (DIBAL-H) The lactone **4** (1.0 g, 2.81 mmol) was dissolved in toluene (100 ml), and the solution cooled to -78°C . Dibal-H solution (3.0 ml, 1.0 M in hexanes, 3 mmol) was added dropwise, while the inside temperature was kept below -70°C throughout the addition. After the addition was completed, the mixture was stirred for 0.5 hours at -78°C . To it was added Ac_2O (5 ml, 53 mmol) and the mixture, with continuous stirring, was allowed to reach room temperature overnight. Water (5 ml) was added to it and the mixture was stirred for 1 hour, MgSO_4 (40 g) was then added, and the mixture was stirred vigorously for 1 hour at room temperature. The mixture was filtered, concentrated, and the residue flash chromatographed with 20% EtOAc in hexanes to give a colorless liquid **5** (0.70 g) which was a mixture of the desired acetates and the aldehyde **3** derived from the ring opening reaction.

Procedure B: ($\text{LiAlH}(\text{OtBu})_2$) Lactone **4** (451.5 mg, 1.27 mmol) was dissolved in 6 ml THF (dry), and cooled to -5°C . To this was added 1.7 ml (1.7 mmol) of a $\text{LiAl}(\text{OtBu})_2\text{H}$ solution (1M in THF; Aldrich) over a 45 minute period. After addition was completed, the mixture was stirred for 7 1/2 hrs. at 0°C . After this time, 1.2 ml (13 mmol, 10 eq) of dry acetic anhydride was added, followed by 78 mg (0.64 mmol, 0.5 equiv.) of DMAP (4-dimethylaminopyridine). The reaction was kept at 0°C for 14 hours, and then quenched at 0°C by adding 1 ml NaHCO_3 and 0.5 g of Na_2CO_3 . The mixture was stirred for 1 hour at 0°C , and then filtered over a 2 inch plug of silica gel (with 6/1-Hexanes/EtOAc), followed by solvent removal to give 930 mg of a yellow oil (1:1.2 ratio at the glycosidic center). Column chromatography (Hexanes/EtOAc, 6/1) gave 332.9 mg of the acetate, which was 90% pure by ^1H NMR (299.6 mg, 59% yield).

(^1H NMR: (CDCl_3 , 300 MHz) 1.02 (s, 9H, major isomer), 1.04 (s, 9H, minor isomer), 1.96 (s, 3H, minor), 2.12 (s, 3H, major), 3.7 (m, 2H),

4.07 (m, 2H), 5.24 (t, 1H, minor, $J=4.2$ Hz), 5.37 (t, 1H, major, $J=3$ Hz), 6.3 (t, 1H, minor, $J=3.9$ Hz), 6.37 (dd, 1H, major, $J=1.5$ Hz, $J=4.5$ Hz), 7.39 (m, 6H), 6.67 (m, 4H). IR (neat): cm^{-1} 3090, 2980, 2880, 1760, 1475, 1435, 1375, 1240, 1120, 1000. MS (FAB, Li^+): 407(M+Li), 312, 282, 241, 197, 162, 125. Anal. Calc. for $\text{C}_{22}\text{H}_{24}\text{O}_5\text{Si}$: C, 65.97%, H, 7.05%; Found: C, 66.60%, H, 7.27%.

The crude acetate **2** (0.25 g, 0.62 mmol, quantity assumed with 0.50 g of the previous mixture) was dissolved in methylene chloride (50 ml), and to it the silylated cytosine **7** ($X = \text{H}$) (0.10 g, 0.63 mmol) was added in one portion. The mixture was stirred for 10 minutes, and to it a TiCl_4 solution (1.30 ml, 1.0 M solution in CH_2Cl_2 , 1.30 mmol) was added, dropwise, at room temperature. It took 2 hours to complete the reaction. Upon completion, the solution was concentrated, the residue was triturated with pyridine (2 ml) and subjected to flash chromatography (first with neat EtOAc then 20% EtOH in EtOAc) to give a tan solid, which was further recrystallized to give a white crystalline solid **2** (0.25 g, 0.55 mmol, 89%). (^1H NMR (CDCl_3 , 300 MHz) 7.97 (1H, d, H_a , $J=7.8$ Hz), 7.67 & 7.40 (10H, m, aromatic-H), 6.24 (1H, d, H_1), 5.62 (1H, d, H_2 , $J=7.6$ Hz), 5.03 (1H, t, H_4), 4.20 (1H, dd, 1H_3 , $J=1.2$ and 9.0 Hz), 4.15 (1H, dd, 1H_3 , $J=4.8$ & 9.0 Hz), 3.96 (1H, dd, 1H_3 , $J=2.1$ and 8.7 Hz), 3.93 (1H, dd, 1H_3 , $J=2.1$ and 8.7 Hz), 1.08 (9H, s, t-Bu).)

Silyl ether **2** (0.12 g, 0.27 mmol) was dissolved in THF (20 ml), and an $n\text{-Bu}_4\text{NF}$ solution (0.30 ml, 1.0 M solution in THF, 0.30 mmol) was added, dropwise, at room temperature. The mixture was stirred for 1 hour and concentrated under vacuum. The residue was taken up with EtOH/pyridine (2 ml/2 ml), and subjected to flash chromatography (first with EtOAc, then 20% EtOH in EtOAc) to afford a white solid, which was further recrystallized from EtOH to give a white crystalline solid **33** (DOC) (55 mg, 0.26 mmol, 96%). (^1H NMR: (DMSO-d_6 , 300 MHz) 7.79

-17-

(1H, d, H_a , $J=7.5$ Hz), 7.18 and 7.11 (2H, broad, NH_2), 6.16 (1H, dd, H_b , $J=3.0$ & 4.2 Hz), 5.70 (1H, d, H_c , $J=7.5$ Hz), 5.16 (1H, t, OH, $J=6.0$ Hz), 4.91 (1H, t, H_d , $J=2.7$ Hz), 4.05 (2H, m, H_e), 3.62 (2H, m, 2 H_f); mp 183-184°C.

The coupling reaction of acetate **5** with silylated thymine **8** showed a titanium species dependent selectivity in accordance with the following observations (ratios were determined by 1H NMR of the crude reaction mixtures):

Titanium Species	$\beta:\alpha$ Ratio
$TiCl_4$	7:1
$TiCl_4(OiPr)$	10:1
$TiCl_4(OiPr)_2$	>98:2

In the coupling reaction using $TiCl_4(OiPr)$, the impure acetate **5** from the procedure B reduction above (assumed 69% of the mixture, 185.4 mg, 0.4653 mmol) was dissolved in 8 ml of dry dichloromethane along with 144 mg (1.15 eq) of silylated thymine **8**, and this mixture was stirred under argon at room temperature. Next 0.57 ml (1.15 eq) of a freshly prepared solution of $TiCl_4(OiPr)$ in dichloromethane (1 M solution prepared from 2 eq of $TiCl_4$ and 1 eq of $TiCl(OiPr)_3$) was added dropwise over a 25 minute period. After 2.5 hours, 0.07 ml (0.15 eq) of a $TiCl_4$ /dichloromethane solution (1 M, Aldrich Chemical Company, Milwaukee, WI) was added and the reaction was stirred for an additional hour. Then 3 ml of ethanol and 5 ml of $NaHCO_3$ solution were added, stirred for 10 minutes, followed by extraction with additional $NaHCO_3$ solution. The aqueous layer was separated, washed twice with 100 ml of dichloromethane, and the organic layers were combined and dried over $MgSO_4$. Filtration, solvent removal, column chromatography (1/2: Hexanes/ $EtOAc$), and then recrystallization (1/1: Hexanes/ Et_2O) gave 160 mg (74%) of compound **6** as a white powder. (1H NMR: ($CDCl_3$, 300

MHz) 1.06 (s, 9H), 1.68 (s, 3H), 3.91 (t, 2H, $J=3.3$ Hz), 4.14 (d, 2H, $J=3.9$ Hz), 5.06 (t, 1H, $J=3.3$ Hz), 6.34 (t, 1H, $J=3.9$ Hz), 7.4 (m, 6H), 7.7 (m, 4H), 8.62 (bs, 1H). MS (FAB, Li^+): 473 ($\text{M}+\text{Li}$), 409, 307, 241, 197, 154, 127. Anal. Calc. for $\text{C}_{25}\text{H}_{20}\text{O}_3\text{N}_2\text{Si}$: C, 64.35%; H, 6.48%; N, 6.00%; Found: C, 64.42%; H, 6.52%; N, 5.97%.

Alternative Procedure

1.156g (70% by ^1H NMR, 0.809g, 2.02 mmol) of the acetate from Procedure B was dissolved in 25 ml of CH_2Cl_2 with 640 mg (1.15 equiv.) of silylated fluorocytosine. Next, 2.222 mmol of $\text{TiCl}_4(\text{OiPr})_2$ was added as a solution with 6 ml CH_2Cl_2 (see previous experimental for $\text{TiCl}_4(\text{OiPr})_2$ preparation), over a 70 minute period. After 2 hours total time, 1.1 ml of $\text{TiCl}_4/\text{CH}_2\text{Cl}_2$ (1 ml solution, Aldrich, 0.55 equiv.) was added over 45 minutes. This mixture was then stirred for 16 hours, and then an additional 0.3 ml. of $\text{TiCl}_4/\text{CH}_2\text{Cl}_2$ was added with stirring for 2 more hours. The mixture was then sequentially quenched with 20 ml of water for 30 minutes, followed by filtration over 2 inches of silica gel with 6/1-EtOAc/EtOH, followed by solvent removal gave 1.28 g of a yellowish form (9:1 B: α by ^1H NMR). Column Chromatography (6/1-EtOAc/EtOH) gave 490 mg (52% yield) of the coupled product as a white powder.

In the coupling reaction using $\text{TiCl}_4(\text{OiPr})_2$, impure acetate from the procedure B reduction (assumed 50% of the mixture, 444 mg, 1.11 mmol) was dissolved in 18 ml of dry dichloromethane along with 654.1 mg of silylated thymine **2** and stirred at room temperature under argon. Next, 1.3 ml of a 2 M $\text{TiCl}_4(\text{OiPr})_2/\text{CH}_2\text{Cl}_2$ solution was added over a 20 minute period. After 14 hours, 1 ml of a 1 M $\text{TiCl}_4/\text{CH}_2\text{Cl}_2$ solution was added and the reaction was stirred for an additional 3 hours. Then 4 ml of concentrated NH_4OH was added, along with 10 ml of dichloromethane. Ten minutes of stirring followed by filtration over 1 inch of silica gel with

EtOAc, solvent removal and then column chromatography of the resulting oil gave 164.9 mg (32%) of compound 10.

The silyl ether 6 (60.9 mg, 0.131 mmol) was dissolved in 2 ml of THF and 0.14 ml of a Bu₄NF/THF solution (1 M, Aldrich) was added. After stirring for 24 hours, the solvent was removed in a vacuum and column chromatography (5/1: EtOAc/EtOH) of the resulting oil gave 22.6 mg (76%) of the desired nucleoside 11 (DOT) as a white powder. (¹H NMR: (HOD (4.8 ppm), 300 MHz) 1.83 (s, 3H), 3.82 (m, 2H), 4.18 (dd, 1H, J=10.5 Hz, J=6 Hz), 5.06 (s, 1H), 6.33 (d, 1H, J=5.7 Hz), 7.72 (s, 1H).

The impure acetate 5 from the procedure B reduction above (assumed 80% by ¹H NMR analysis, 117.6 mg, 0.294 mmol) and 120.8 mg (1.5 eq) of silylated fluorocytosine 7 (X = F) were dissolved in 10 ml of dry dichloromethane. Then 0.59 ml (2 eq) of a TiCl₄/dichloromethane solution was added dropwise over 1 hour. After stirring for 30 additional minutes, 5 ml of dichloromethane and 1 ml of concentrated NH₄OH were added, the solvent was removed in a vacuum, and column chromatography (EtOAc/EtOH: 1/1) gave 35 mg (25%) of compound 12 as a white solid. (¹H NMR: (CDCl₃, 300 MHz) 1.06 (s, 9H), 3.62 (dq, 2H, J=2.7 Hz, J=12.3 Hz), 3.9 (m, 2H), 5.01 (t, 1H, J=2.4 Hz), 6.2 (m, 1H), 7.41 (m, 6H), 7.7 (m, 4H), 7.92 (d, 1H, J=6 Hz).)

The silyl ether 12 (116.8 MG, 0.249 mmol) was dissolved in 3 ml of dry THF, and 0.3 ml of a Bu₄NF/THF solution (1M, Aldrich Chemical Company, Milwaukee, WI) was added. After 3 hours of stirring, the solvent was removed by vacuum, and column chromatography (EtOAc/EtOH: 4/1) gave 48.1 mg (84%) of the nucleoside 13 (FDOC) as a white powder. (¹H NMR: (DMSO-d₆, 300 MHz) 3.63 (m, 2H), 4.01 (dd, 1H, J=5.1 Hz, J=9.6 Hz), 4.08 (d, 1H, J=9.6 Hz), 4.87 (s, 1H),

5.26 (t, 1H, J=6 Hz), 6.07 (m, 1H), 7.49 (bs, 1H), 7.73 (bs, 1H), 8.12 (d, 1H, J=7.2 Hz).

II. Process for the Resolution of C4'-Racemic Mixtures of 1,3-Dioxolane Nucleosides

A method is provided for the resolution of racemic mixtures of C4'-nucleoside enantiomers of 1,3-dioxolane nucleosides. The method involves the use of enzymes for which one enantiomer is a substrate and the other enantiomer is not. The enzyme catalyses the reaction in the "recognized" enantiomer, and then the reacted enantiomer is separated from the unreacted enantiomer on the basis of the new difference in physical structure. Given the disclosure herein, one of skill in the art will be able to choose an enzyme that is selective for the nucleoside enantiomer of choice (or selective for the undesired enantiomer, as a method of eliminating it), by selecting of one of the enzymes discussed below or by systematic evaluation of other known enzymes. Given this disclosure, one of skill in the art will also know how to modify the substrate as necessary to attain the desired resolution. Through the use of either chiral NMR shift reagents or polarimetry, the optical enrichment of the recovered ester can be determined.

The following examples further illustrate the use of enzymes to resolve racemic mixtures of enantiomers. Other known methods of resolution of racemic mixtures can be used in combination with the method of resolution disclosed herein. All of these modifications are considered within the scope of the invention. The following examples are not intended to limit the scope of the invention.

Resolution Based on Hydrolysis of C5'-Nucleoside Esters

In one embodiment, the method includes reacting the C5'-hydroxyl group of a mixture of 1,3-dioxolane nucleoside racemates with an acyl

compound to form C5'-esters in which the nucleoside is in the "carbinol" end of the ester. The racemic mixture of nucleoside C5'-esters is then treated with an enzyme that preferentially cleaves, or hydrolyses, one of the enantiomers and not the other.

An advantage of this method is that it can be used to resolve a wide variety of nucleosides, including pyrimidine and purine nucleosides that are optionally substituted in the carbohydrate moiety or base moiety. The broad applicability of this method resides in part on the fact that although the carbinol portion of the ester plays a role in the ability of an enzyme to differentiate enantiomers, the major recognition site for these enzymes is in the carboxylic acid portion of the ester. Further, one may be able to successfully extrapolate the results of one enzyme/substrate study to another, seemingly-different system, provided that the carboxylic acid portions of the two substrates are the same or substantially similar.

Another advantage of this method is that it is regioselective. Enzymes that hydrolyse esters typically do not catalyze extraneous reactions in other portions of the molecule. For example, the enzyme lipase catalyses the hydrolysis of the ester of 2-hydroxymethyl-5-oxo-1,3-oxathiolane without hydrolysing the internal lactone. This contrasts markedly with "chemical" approaches to ester hydrolysis.

Still another advantage of this method is that the separation of the unhydrolysed enantiomer and the hydrolysed enantiomer from the reaction mixture is quite simple. The unhydrolysed enantiomer is more lipophilic than the hydrolysed enantiomer and can be efficiently recovered by simple extraction with one of a wide variety of nonpolar organic solvents or solvent mixtures, including hexane and hexane/ether. The less lipophilic, more polar hydrolysed enantiomer can then be obtained by extraction with a more polar organic solvent, for example, ethyl acetate, or by lyophilization, followed by extraction with ethanol or methanol. Alcohol

should be avoided during the hydrolysis because it can denature enzymes under certain conditions.

Enzymes and Substrates

With the proper matching of enzyme and substrate, conditions can be established for the isolation of either nucleoside enantiomer. The desired enantiomer can be isolated by treatment of the racemic mixture with an enzyme that hydrolyses the desired enantiomer (followed by extraction of the polar hydrolysate with a polar solvent) or by treatment with an enzyme that hydrolyses the undesired enantiomer (followed by removal of the undesired enantiomer with a nonpolar solvent).

Enzymes that catalyze the hydrolysis of esters include esterases, for example pig liver esterase, lipases, including porcine pancreatic lipase and Amano PS-800 lipase, subtilisin, and α -chymotrypsin.

The most effective acyl group to be used to esterify the C5'-position of the nucleoside can be determined without undue experimentation by evaluation of a number of homologs using the selected enzyme system. For example, when 1,3-oxathiolane nucleosides are esterified with butyric acid, resolutions with both pig liver esterase and Amano PS-800 proceed with high enantioselectivity (94-100 enantiomeric excess) and opposite selectivity. Non-limiting examples of other acyl groups that can be evaluated for use with a particular nucleoside enantiomeric mixture and particular enzyme include alkyl carboxylic acids and substituted alkyl carboxylic acids, including acetic acid, propionic acid, butyric acid, and pentanoic acid. With certain enzymes, it may be preferred to use an acyl compound that is significantly electron-withdrawing to facilitate hydrolysis by weakening the ester bond. Examples of electron-withdrawing acyl groups include α -haloesters such as 2-chloropropionic acid, 2-chlorobutyric acid, and 2-chloropentanoic acid. α -Haloesters are excellent substrates for lipases.

Resolution Conditions

The enzymatic hydrolyses are typically carried out with a catalytic amount of the enzyme in an aqueous buffer that has a pH that is close to the optimum pH for the enzyme in question. As the reaction proceeds, the pH drops as a result of liberated carboxylic acid. Aqueous base should be added to maintain the pH near the optimum value for the enzyme. The progress of the reaction can be easily determined by monitoring the change in pH and the amount of base needed to maintain pH. The hydrophobic ester (the unhydrolysed enantiomer) and the more polar alcohol (the hydrolysed enantiomer) can be sequentially and selectively extracted from the solution by the judicious choice of organic solvents. Alternatively, the material to be resolved can be passed through a column that contains the enzyme immobilized on a solid support.

Enzymatic hydrolyses performed under heterogeneous conditions can suffer from poor reproducibility. Therefore, it is preferred that the hydrolysis be performed under homogeneous conditions. Alcohol solvents are not preferred because they can denature the enzymes. Cosolvents that do not denature enzymes should be used, such as acetonitrile. Homogeneity can be achieved through the use of non-ionic surfactants, such as Triton X-100. However, addition of these surfactants not only assists in dissolving the starting material, they also enhances the aqueous solubility of the product. Therefore, although the enzymatic reaction can proceed more effectively with the addition of a non-ionic surfactant than under heterogeneous conditions, the isolation of both the recovered starting material and the product can be made more difficult. The product can be isolated with appropriate chromatographic and chemical (e.g., selective salt formation) techniques. Diacylated nucleosides can be used but are often quite lipophilic and hard to dissolve in the medium used.

B. Therapeutic Use of 1,3-Dioxolane Nucleosides

A number of compounds made according to this invention either possess antiretroviral activity, such as anti-HIV-1, anti-HIV-2 and anti-simian immunodeficiency virus (anti-SIV) activity, themselves and/or are metabolizable to species that possess antiretroviral activity. Thus, these compounds, pharmaceutically acceptable derivatives or salts of these compounds or pharmaceutically acceptable formulations containing these compounds or their derivatives are useful in the prevention and treatment of viral infections in a host such as a human, preferably HIV infections and other AIDS-related conditions such as AIDS-related complex (ARC), persistent generalized lymphadenopathy (PGL), AIDS-related neurological conditions, anti-HIV antibody positive and HIV-positive conditions, Kaposi's sarcoma, thrombocytopenia purpurea and opportunistic infections. In addition, these compounds or formulations can be used prophylactically to prevent or retard the progression of clinical illness in individuals who are anti-HIV antibody or HIV-antigen positive or who have been exposed to HIV.

Thus, humans can be treated by administering to the patient a pharmaceutically effective amount of the active nucleoside prodrug analogues in the presence of a pharmaceutically acceptable carrier or diluent such as a liposomal suspension. A preferred carrier for oral administration is water, especially sterilized water. If administered intravenously, the preferred carriers are physiological saline or phosphate buffered saline. The compounds according to the present invention are included in the pharmaceutically acceptable carrier in an amount sufficient to exert a therapeutically useful inhibitory effect on HIV in vivo without exhibiting adverse toxic effects on the patient treated. Pharmaceutically compatible binding agents and/or adjuvant materials may also be included as part of the composition. The active materials can also be mixed with

other active materials that do not impair the desired action and/or supplement the desired action.

It will be appreciated by those skilled in the art that the effective amount of a compound or formulation containing the compound required to treat an individual will vary depending on a number of factors, including whether the compound or a prodrug analogue is administered, the route of administration, the nature of the condition being treated and the age and condition of the patient. In general, however, an effective dose for all of the above-described conditions, will range from about 1-50 mg per kg body weight of the patient per day, preferably 1-20 mg/kg/day, and more generally, 0.1 to 100 mg per kilogram per day. Preferably, a dose will produce peak blood levels of the active compound that range from about, 0.2 to 70 μM , preferably 1-10 μM , and most preferably about 5 μM . The desired dose may be given in a single dose or as divided doses administered at appropriate intervals, such as two, three, four or more sub-doses per day.

Thus, the active compounds, or derivatives or salts thereof, or formulations containing these compounds or their pharmaceutically acceptable derivatives or salts, can be conveniently administered by any convenient route of administration, such as parenteral, including intramuscular, subcutaneous and intravenous; oral; rectal; nasal; vaginal or by inhalation. The compounds can be administered in unit dosage form for all of the above-identified conditions, such as formulations containing 7 to 3000 mg, preferably 70 to 1400 mg, and most preferably, 1 to 10 mg of active ingredient per unit dosage form.



A preferred mode of administration of the compounds of this invention is oral. Oral compositions will generally include an inert diluent or an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic

administration, the compounds of this invention may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gums and the like. An oral dosage of 50-1000 mg is usually convenient.

The active compound can be administered as any derivative that upon administration to the recipient, is capable of providing directly or indirectly, the parent compound, or that exhibits activity itself. Nonlimiting examples are the pharmaceutically acceptable salts (alternatively referred to as "physiologically acceptable salts"), and the 5' and N' acylated or alkylated derivatives of the active compound (alternatively referred to as "physiologically active derivatives"). In one embodiment, the acyl group is a carboxylic acid ester in which the non-carbonyl moiety of the ester group is selected from straight, branched, or cyclic alkyl, alkoxyalkyl including methoxymethyl, aralkyl including benzyl, aryloxyalkyl such as phenoxymethyl, aryl including phenyl optionally substituted with halogen, C₁ to C₄ alkyl or C₁ to C₄ alkoxy, sulfonate esters such as alkyl or aralkyl sulphonyl including methanesulfonyl, the mono, di or triphosphate ester, trityl or monomethoxytrityl, substituted benzyl, trialkylsilyl (e.g. dimethyl-t-butylsilyl) or diphenylmethylsilyl. Aryl groups in the esters optimally comprise a phenyl group. The alkyl group can be straight, branched, or cyclic, and is optimally a C₁ to C₁₁ group.

-27-

Specific examples of pharmaceutically acceptable derivatives include, but are not limited to:



wherein R_1 and R_2 are independently selected from the group consisting of alkyl and acyl, specifically including but not limited to methyl, ethyl, propyl, butyl, pentyl, hexyl, isopropyl, isobutyl, sec-butyl, t-butyl, isopentyl, amyl, t-pentyl, 3-methylbutyryl, hydrogen succinate, 3-chlorobenzoate, cyclopentyl, cyclohexyl, benzoyl, acetyl, pivaloyl, mesylate, propionyl, butyryl, valeryl, caproic, caprylic, capric, lauric, myristic, palmitic, stearic, oleic, amino acids including but not limited to alanyl, valinyl, leucinyl, isoleucinyl, prolinyl, phenylalaninyl, tryptophanyl, methioninyl, glycyl, serinyl, threoninyl, cysteinyl, tyrosinyl, asparaginyl, glutaminyl, aspartoyl, glutaoyl, lysinyl, argininyl, and histidinyl, and wherein one of R_1 and R_2 can be H.

Derivatives can be provided in the form of pharmaceutically acceptable salts. As used herein, the term pharmaceutically acceptable salts or complexes refers to salts or complexes that retain the desired biological activity of the parent compound and exhibit minimal, if any, undesired toxicological effects. Nonlimiting examples of such salts are (a) acid addition salts formed with inorganic acids (for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), and salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pantoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acids, naphthalenedisulfonic acids, and polygalacturonic acid; (b) base addition salts formed with polyvalent metal cations such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel, cadmium, sodium, potassium, and the like, or with an organic cation formed from N,N-dibenzylethylene-diamine, ammonium, or ethylenediamine; or (c) combinations of (a) and (b); e.g., a zinc tannate salt or the like.

Modifications of the active compound, specifically at the N⁴ and 5'-O positions, can affect the bioavailability and rate of metabolism of the active species, thus providing control over the delivery of the active species. Further, the modifications can affect the antiviral activity of the compound, in some cases increasing the activity over the parent compound. This can easily be assessed by preparing the derivative and testing its antiviral activity according to the methods described herein, or other method known to those skilled in the art.

Methodology for Testing Antiviral Activity

Antiviral compositions can be screened in vitro for inhibition of HIV by various experimental techniques. One such technique involves measuring the inhibition of viral replication in human peripheral blood mononuclear (PBM) cells. The amount of virus produced is determined

by measuring the quantity of virus coded reverse transcriptase (RT), an enzyme found in retroviruses, that is present in the cell culture medium.

PBM cells from healthy HIV-1 and hepatitis B virus seronegative donors were isolated by Ficoll-Hypaque discontinuous gradient centrifugation at 1,000 x g for 30 minutes, washed twice in PBS and pelleted at 300 x g for 10 minutes. Before infection, the cells were stimulated by phytohemagglutinin (PHA) at a concentration of 6 μ g/ml for three days in RPMI 1640 medium supplemented with 15% heat-inactivated fetal calf serum, 1.5 mM L-glutamine, penicillin (100 U/ml), streptomycin (100 μ g/ml), and sodium bicarbonate buffer. most of the antiviral assays described below were performed with cells from at least two different donors.

HIV-1 (strain IAV-1) was obtained from the Centers for Disease Control, Atlanta, and propagated in PHA-stimulated human PBM cells using RPMI 1640 medium as above without PHA and supplemented with 7% interleukin-2 (Advanced Biotechnologies, Silver Spring, MD), 7 μ g/ml DEAE-dextran (Pharmacia, Uppsala, Sweden), and 370 U/ml anti-human leukocyte (alpha) interferon (ICN, Lisle, IL). Virus was obtained from the cell free culture supernatant and stored in aliquots at -70°C until used.

Uninfected PHA-stimulated human PBM cells were uniformly distributed among 25 cm² flasks to give a 5 ml suspension containing about 2×10^6 cells/ml. Suitable dilutions of HIV were added to infect the cultures so that the mean reverse transcriptase (RT) activity of the inocula was 50,000 dpm/ml, which was equivalent to about 100 TCID₅₀, determined as described in AIDS Res. Human Retro, 3:71-85 (1987). The drugs, at twice their final concentrations in 5 ml of RPMI 1640 medium, supplemented as described above, were added to the cultures. Uninfected and treated PBM cells were grown in parallel as controls. The cultures were maintained in a humidified 5% CO₂-95% air incubators at 37°C for

five days after infection, at which point all cultures were sampled for supernatant RT activity. Previous studies indicate that the maximum RT levels are obtained at that time.

The RT assay was performed by a modification of the Spira et al., J. Clin. Microbiol., 25, 97-99 (1987) method in 96well microtiter plates. The radioactive cocktail (180 μ l), which contained 50 mM Tris-HCl pH 7.8, 9 mM MgCl₂, 5 mM dithiothreitol 4.7 μ g/ml (rA), (dT)₁₂₋₁₈, 140 μ M dATP and 0.22 μ M [³H]TTP (specific activity 78.0 Ci/mmol, equivalent to 17,300 cpm/pmol; KEN Research Products, Boston, MA), was added to each well. The sample (20 μ l) was added to the reaction mixture and incubated at 37°C for two hours. The reaction was terminated by the addition of 100 μ l cold 10% trichloroacetic acid (TCA) containing 0.45 mM sodium pyrophosphate. The acid insoluble nucleic acid which precipitated was collected on glass filters using a Skatron semiautomatic harvester (setting 9). The filters were washed with 5% TCA and 70% ethanol, dried, and placed in scintillation vials. Four ml of scintillation fluid (Econofluor, NEN Research Products, Boston MA) was added and the amount of radioactivity in each sample determined using a Packard Tri-Carb liquid scintillation analyzer (model 2,000CA). The results were expressed in dpm/ml of original clarified supernatant. The antiviral activity, expressed as the micromolar concentration of compound that inhibits replication of the virus by 50% (EC₅₀), was calculated by determining the percent inhibition by the median effect method described in Chou and Talalay, Adv. Enz. Regul., 22:27-55 (1984).

Methodology for Testing Toxicity and Inhibition of Cell Proliferation

The compounds were evaluated for their potential toxic effects on uninfected PRA-stimulated human PBM cells and also in CEM (T-lymphoblastoid cell line obtained from ATCC, Rockville, MD) and Vero (African Green Monkey kidney) cells. PBM cells were obtained

from whole blood of healthy HIV and hepatitis-B seronegative volunteers and collected by a single-step FicollHypaque discontinuous gradient centrifugation. The CEM cells were maintained in RPMI 1640 medium supplemented with 20% heat inactivated fetal calf serum, penicillin (100 U/ml), and streptomycin (100 µg/ml). Flasks were seeded so that the final cell concentration was 3×10^5 cells/ml. The PBM and CEM cells were cultured with and without drug for 6 days at which time aliquots were counted for cell proliferation and viability using the trypan blue-exclusion method (Sommadossi et al, Antimicrob. Agents Chemother., 32:997-1001 (1988). Only the effects on cell growth are reported because these correlated well with cell viability. The toxicity of the compounds in Vero cells was assessed after 3 days of treatment with a hemacytometer as described in Schinazi et al, Antimicrobe Agents Chemother., 22:499-507 (1982). The toxicity, expressed as the micromolar concentration of compound that inhibits the growth of normal cells by 50% (IC_{50}), was determined, similarly to EC_{50} , by the method of Chou and Talalay.

EXAMPLE 2 ANTIVIRAL AND CYTOTOXICITY ASSAYS OF 1,3-DIOXOLANE NUCLEOSIDES

Table 1 below lists the results of anti-HIV-1 activity in human PBM cells and toxicity assays in human PBM cells, Vero (African Green Monkey kidney) cells, and CEM cells for 2'-deoxy-3'-oxacytidine (DOC), 2'-deoxy-3'-oxathymidine (DOT), 2'-deoxy-5-fluoro-3'-oxacytidine (FDOC) and 2'-deoxy-5-fluoro-3'-oxauridine (FDOU).


Table 1

ANTI-HIV ACTIVITY		CYTOTOXICITY		
Antiviral Drug	EC ₅₀ μ M (PBM)	IC ₅₀ μ M (PBM)	IC ₅₀ μ m (Vero)	IC ₅₀ μ M (CEM)
DOC	0.0047	>200	0.17	<1
DOT	0.09	>100	>100	
FDOC	0.0063	>200	<0.1	<1
FDOU	>10	>200	>100	>100
FDOC(+)	0.027			
FDOC(-)	0.013			

This invention has been described with reference to its preferred embodiments. Variations and modifications of the invention, will be obvious to those skilled in the art from the foregoing detailed description of the invention. It is intended that all of these variations and modifications be included within the scope of the appended claims.

We claim:

1. A process for the preparation of 1,3-dioxolane nucleosides that includes reacting a 2-O-protected-5-O-acylated-1,3-dioxolane with a protected purine or pyrimidine base in the presence of a titanium catalyst of the formula:



wherein $m = 4$; $n = 2, 3$, or 4 ; Ti = titanium; $\text{X} = \text{Cl}, \text{Br}$, or I ; and Y is alkoxy, aryloxy, amino, alkylamino, dialkylamino, arylamino, diarylamino, alkylarylamino, and mixtures thereof, or a bifunctional molecule that contains both an alkoxy and an amino functional group and that is bound to the titanium molecule by both the alkoxy and amino moieties, to provide predominately the desired β -isomer in the C1' -position of a 1,3-dioxolane nucleoside.

2. The method of claim 1, wherein the titanium catalyst is selected from the group consisting of TiCl_4 , $\text{TiCl}_4(\text{OiPr})_2$, and $\text{TiCl}_4(\text{OiPr})$.

3. The method of claim 1, wherein the 1,3-dioxolane nucleoside is 2-hydroxymethyl-5-(thymidin-1-yl)-1,3-dioxolane.

4. The method of claim 1, wherein the purine or pyrimidine base is selected from the group consisting of cytosine, thymine, uracil, adenine, guanine, and alkylated, sulfonylated, alkoxyated, and halogenated derivatives thereof.

5. The method of claim 1, wherein the alkoxy group is lower alkoxy (C_1 or less).

6. The method of claim 1, wherein the alkylamino group contains a lower alkyl group (C_1 or less).

7. The method of claim 1, wherein the bifunctional molecule is selected from the group consisting of 2-aminoethanol, 3-aminopropanol, and 1-substituted and 2-substituted derivatives thereof in which the substituents are lower alkyl (C_1 or less) or aryl groups.

8. A method for the resolution of a racemic mixture of 1,3-dioxolane nucleoside enantiomers, comprising the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers.

9. The method of claim 8, wherein the enzyme is selected from the group consisting of an esterase, a lipase, subtilisin, α -chymotrypsin, and cytidine-deoxycytidine deaminase.

10. The method of claim 9, wherein the esterase is pig liver esterase.

11. The method of claim 9, wherein the lipase is selected from the group consisting of porcine pancreatic lipase and Amano PS-800 lipase.

12. The method of claim 8, wherein the nucleoside enantiomers are acylated at the C5'-hydroxyl position.

13. The method of claim 12, wherein the enantiomers are acylated before resolution with a compound selected from the group consisting of alkyl carboxylic acids and substituted alkyl carboxylic acids.

14. The method of claim 13, wherein the alkyl carboxylic acid is selected from the group consisting of acetic acid, propionic acid, butyric acid, pentanoic acid, 2-chloropropionic acid, 2-chlorobutyric acid, and 2-chloropentanoic acid.

15. The method of claim 8, wherein the nucleoside enantiomers are passed through a column that includes the enzyme immobilized on a support.

16. The method of claim 8, wherein the enantiomers are mixed with the enzyme in a solution.

17. The method of claim 8, further comprising carrying out the enzymatic reaction in the presence of a non-ionic surfactant.

18. The method of claim 17, wherein the non-ionic surfactant is Triton X-100.

19. The method of claim 8, further comprising the step of exposing the product of resolution to a second enzyme that enhances the resolution.

20. The method of claim 8, further comprising recrystallizing the product of resolution.

21. The method of claim 8, further comprising treating the product of resolution with a chiral acid.

22. The method of claim 21, wherein the chiral acid is selected from the group consisting of malic acid, mandelic acid, dibenzoyl tartaric acid, 3-bromocamphor-8-sulfonic acid, 10-camphorsulfonic acid, and di-p-toluoyltartaric acid.

23. The method of claim 1, wherein the 1,3-dioxolane nucleoside is 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-dioxolane.

24. (\pm)-2'-Deoxy-5-fluoro-3'-oxacytidine.


25. (-)-2'-Deoxy-5-fluoro-3'-oxacytidine.

26. (+)-2'-Deoxy-5-fluoro-3'-oxacytidine.

27. (\pm)- β -D,L-2'-Deoxy-5-fluoro-3'-oxacytidine, its (-) and (+) enantiomers, and pharmaceutically acceptable derivatives and salts thereof for use in medical therapy, for example for the treatment or prophylaxis of an HIV infection;

28. Use of (\pm)- β -D,L-(\pm)- β -D,L-2'-Deoxy-5-fluoro-3'-oxacytidine, its (-) and (+) enantiomers, and pharmaceutically acceptable derivatives and salts thereof in the manufacture of a medicament for treatment of an HIV infection.

1/2



1, 3 - Dioxolane Nucleoside

wherein:


B = purine or pyrimidine base

X = C4' chiral carbon atom

Y = C1' chiral carbon atom

FIGURE 1

FIGURE 2



INTERNATIONAL SEARCH REPORT

PCT/US92/01393

International Application No.

I. CLASSIFICATION OF SUBJECT MATTER (in several classification symbols apply, indicate all)

According to International Patent Classification (IPC) or to both National Classification and IPC
 IPC(5): C07D 411/04, C07F 5/04, A61K 31/505
 US CL: 544/229, 276, 277, 310, 313, 314, 317; 514/262, 266, 274

II. FIELDS SEARCHED

Minimum Documentation Searched

Classification System

Classification Symbols

U.S.

544/229, 276, 277, 310, 313, 314, 317; 514/262, 266, 274

Documentation Searched other than Minimum Documentation
 to the extent that such Documents are included in the Fields Searched

III. DOCUMENTS CONSIDERED TO BE RELEVANT

Category * Citation of Document, ** with indication, where appropriate, of the relevant passages ** Relevant to Claim No. **

P, Y	US 5,047,407 (IAF BIOCHEM. International, Inc.) 10 September 1991. See entire document	24-28
A	US 4,916,122 (University of Georgia Research Founda- 10 April 1990. See entire document	1-7, 23-28
X	EP 337,713 (IAF BIOCHEM INT. INC.) 18 October 1989 See pages 4-5, formula L, claims 1, 13-15	24-28
P, Y	US, 5,041,449 (IAF Biochem International Inc.) 20 August 1991, See col. 3-4, formula L. claims 1 and 6.	24-28
Y	EP 382,526 (IAF BIOCHEM International Inc.) 16 August 1990, see entire document	24-28
P, Y	Antimicrobial Agents and chemotherapy vol. 35, no. 7 (1991). Hugo soudeyns et al, "Anti-human Immuno- deficiency Virus Type 1 Activity and In Vitro Toxicity of 2'-Deoxy-3'-Thiacytidine (BCH-189), a Novel Heterocyclic Nucleoside Analog" pp 1386-1390	24-28

* Special categories of cited documents: *

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

30 June 1992

International Searching Authority

ISA/US

Date of Making of the International Search Report

31 JUL 1992

Signature of Authorizing Officer

Cecilia Tsang

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers _____ because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claim numbers _____ because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out², specifically:

3. ☐ Claim numbers _____ because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING³

This international Searching Authority found multiple inventions in this international application as follows:

I. Claims 1-7 and 23-28, drawn to 1,3-dioxolane nucleosides, composition, method of use and process of preparation.

II. Claims 8-22, drawn to resolution of racemic mixture.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

1-7 and 23-28

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

☐ The additional search fees were accompanied by applicant's protest.

☐ No protest accompanied the payment of additional search fees.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.